联合治疗-话题@MedSci

#联合治疗#

277篇内容 | 2103人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1313857, encodeId=0187131385ed3, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Thorac Cancer：卡铂+白蛋白-紫杉醇联合治疗复发性小细胞肺癌（SCLC）的疗效, objectType=article, longId=301524, objectId=dfda301524c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dfda301524c5, replyNumber=0, likeNumber=46, createdTime=2022-03-25, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dfda301524c5, moduleTitle=Thorac Cancer：卡铂+白蛋白-紫杉醇联合治疗复发性小细胞肺癌（SCLC）的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dfda301524c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313856, encodeId=625d131385656, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Oncologist：西妥昔单抗+伊立替康+贝伐单抗联合治疗未能改善伊立替康难治性转移性结直肠癌(mCRC)的患者PFS，但可改善OS, objectType=article, longId=300705, objectId=242e300e0568, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=242e300e0568, replyNumber=0, likeNumber=56, createdTime=2022-03-15, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=242e300e0568, moduleTitle=Oncologist：西妥昔单抗+伊立替康+贝伐单抗联合治疗未能改善伊立替康难治性转移性结直肠癌(mCRC)的患者PFS，但可改善OS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=242e300e0568)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313855, encodeId=1b8b13138559a, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=硫胺素、维生素 C 和氢化可的松联合治疗脓毒症和感染性休克, objectType=article, longId=299754, objectId=31b1299e54a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=31b1299e54a9, replyNumber=0, likeNumber=52, createdTime=2022-03-01, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=31b1299e54a9, moduleTitle=硫胺素、维生素 C 和氢化可的松联合治疗脓毒症和感染性休克, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=31b1299e54a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313854, encodeId=256b13138544e, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Front Oncol：III期临床研究XELAVIRI评估一线贝伐珠单抗为基础的续观治疗对比联合治疗转移性结直肠癌（mCRC）患者的疗效, objectType=article, longId=299336, objectId=5af529933624, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5af529933624, replyNumber=0, likeNumber=38, createdTime=2022-02-23, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5af529933624, moduleTitle=Front Oncol：III期临床研究XELAVIRI评估一线贝伐珠单抗为基础的续观治疗对比联合治疗转移性结直肠癌（mCRC）患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5af529933624)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313853, encodeId=503c13138532f, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=LEUKEMIA：Erk1/2i 和 CDK4/6i 联合治疗复发难治性多发性骨髓瘤, objectType=article, longId=299159, objectId=5c4f2991594a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5c4f2991594a, replyNumber=0, likeNumber=44, createdTime=2022-02-20, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5c4f2991594a, moduleTitle=LEUKEMIA：Erk1/2i 和 CDK4/6i 联合治疗复发难治性多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5c4f2991594a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313852, encodeId=5a9113138526f, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=JAMA子刊：ICS/LABA联合治疗对早产儿相关肺部疾病有益, objectType=article, longId=295767, objectId=def0295e678b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=def0295e678b, replyNumber=0, likeNumber=36, createdTime=2022-02-17, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=def0295e678b, moduleTitle=JAMA子刊：ICS/LABA联合治疗对早产儿相关肺部疾病有益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=def0295e678b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313851, encodeId=7564131385100, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=BMC Cancer：韩国回顾性队列研究：非糖尿病血脂异常患者的降脂药物依从性和联合治疗对胃肠道肿瘤的影响, objectType=article, longId=295575, objectId=b9ae2955e59e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b9ae2955e59e, replyNumber=0, likeNumber=0, createdTime=2022-02-15, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b9ae2955e59e, moduleTitle=BMC Cancer：韩国回顾性队列研究：非糖尿病血脂异常患者的降脂药物依从性和联合治疗对胃肠道肿瘤的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b9ae2955e59e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313849, encodeId=825e1313849d7, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Transl Lung Cancer Res: 在EGFR突变晚期NSCLC患者使用EGFR-TKI治疗失败后，化疗-抗血管生成对比化疗-免疫治疗联合治疗的疗效, objectType=article, longId=295276, objectId=d9be2952e62d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9be2952e62d, replyNumber=0, likeNumber=31, createdTime=2022-02-10, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9be2952e62d, moduleTitle=Transl Lung Cancer Res: 在EGFR突变晚期NSCLC患者使用EGFR-TKI治疗失败后，化疗-抗血管生成对比化疗-免疫治疗联合治疗的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d9be2952e62d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313850, encodeId=5d86131385002, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Transl Lung Cancer Res: Pembrolizumab（帕博利珠单抗）单药或联合治疗晚期非小细胞肺癌伴骨转移患者的疗效, objectType=article, longId=295254, objectId=ccd329525402, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ccd329525402, replyNumber=0, likeNumber=32, createdTime=2022-02-09, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ccd329525402, moduleTitle=Transl Lung Cancer Res: Pembrolizumab（帕博利珠单抗）单药或联合治疗晚期非小细胞肺癌伴骨转移患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ccd329525402)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313848, encodeId=4f6f13138484c, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=NEJM：纳武单抗联合治疗对晚期食管鳞状细胞癌的疗效分析, objectType=article, longId=295127, objectId=119b29512e22, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=119b29512e22, replyNumber=0, likeNumber=34, createdTime=2022-02-06, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=119b29512e22, moduleTitle=NEJM：纳武单抗联合治疗对晚期食管鳞状细胞癌的疗效分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=119b29512e22)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313847, encodeId=9b70131384e5d, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Front Immunol：联合治疗通过抑制Caspase-1/Gasdermin D诱导狼疮性肾炎细胞焦亡的新作用, objectType=article, longId=294149, objectId=12f429414970, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=12f429414970, replyNumber=0, likeNumber=46, createdTime=2022-01-19, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=12f429414970, moduleTitle=Front Immunol：联合治疗通过抑制Caspase-1/Gasdermin D诱导狼疮性肾炎细胞焦亡的新作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=12f429414970)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313846, encodeId=257213138468a, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=BMC Cancer：曲妥珠单抗和氟维司群联合治疗HR+/HER2+转移性乳腺癌患者的疗效和安全性, objectType=article, longId=293700, objectId=baae293e00d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=baae293e00d8, replyNumber=0, likeNumber=38, createdTime=2022-01-12, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=baae293e00d8, moduleTitle=BMC Cancer：曲妥珠单抗和氟维司群联合治疗HR+/HER2+转移性乳腺癌患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=baae293e00d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313845, encodeId=13a5131384590, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Chin J Cancer Res：阿帕替尼单药或联合治疗HER2阴性乳腺癌伴有胸壁转移患者的疗效：多中心II期临床研究, objectType=article, longId=292393, objectId=a3232923933c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a3232923933c, replyNumber=0, likeNumber=40, createdTime=2021-12-22, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a3232923933c, moduleTitle=Chin J Cancer Res：阿帕替尼单药或联合治疗HER2阴性乳腺癌伴有胸壁转移患者的疗效：多中心II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a3232923933c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313844, encodeId=0668131384420, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=辉瑞疫苗对奥密克戎的中和活性降低40多倍，我国新冠病毒中和抗体联合治疗药物获批丨新冠研究一周进展, objectType=article, longId=291882, objectId=027e29188207, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=027e29188207, replyNumber=0, likeNumber=0, createdTime=2021-12-16, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=027e29188207, moduleTitle=辉瑞疫苗对奥密克戎的中和活性降低40多倍，我国新冠病毒中和抗体联合治疗药物获批丨新冠研究一周进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=027e29188207)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313843, encodeId=917513138433b, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=雷帕霉素和低剂量伊马替尼联合治疗肺动脉高压, objectType=article, longId=221587, objectId=621422158e74, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=621422158e74, replyNumber=0, likeNumber=36, createdTime=2021-12-07, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=621422158e74, moduleTitle=雷帕霉素和低剂量伊马替尼联合治疗肺动脉高压, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=621422158e74)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313842, encodeId=3352131384202, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=NEJM：绝经状态会影响腋窝淋巴结阳性乳腺癌患者化疗-内分泌联合治疗收益, objectType=article, longId=221513, objectId=0627221513f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0627221513f9, replyNumber=0, likeNumber=0, createdTime=2021-12-05, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0627221513f9, moduleTitle=NEJM：绝经状态会影响腋窝淋巴结阳性乳腺癌患者化疗-内分泌联合治疗收益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0627221513f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313841, encodeId=206f131384148, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=AJKD：利妥昔单抗+低剂量环磷酰胺+强的松联合治疗原发性膜性肾病的疗效, objectType=article, longId=221413, objectId=18d1221413ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=18d1221413ca, replyNumber=0, likeNumber=45, createdTime=2021-12-03, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=18d1221413ca, moduleTitle=AJKD：利妥昔单抗+低剂量环磷酰胺+强的松联合治疗原发性膜性肾病的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=18d1221413ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313840, encodeId=f0dc13138408e, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=ASCO2021:阿特珠单抗+贝伐珠单抗联合治疗对不可切除肝癌有益, objectType=article, longId=221028, objectId=979e22102878, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=979e22102878, replyNumber=0, likeNumber=26, createdTime=2021-11-27, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=979e22102878, moduleTitle=ASCO2021:阿特珠单抗+贝伐珠单抗联合治疗对不可切除肝癌有益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=979e22102878)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313839, encodeId=6c86131383941, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Diabetes Obes Metab：每日2次艾塞那肽和达格列净单药或联合治疗对2型糖尿病肥胖患者肾功能标志物的影响, objectType=article, longId=219738, objectId=782b219e38c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=782b219e38c6, replyNumber=0, likeNumber=25, createdTime=2021-11-05, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=782b219e38c6, moduleTitle=Diabetes Obes Metab：每日2次艾塞那肽和达格列净单药或联合治疗对2型糖尿病肥胖患者肾功能标志物的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=782b219e38c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313837, encodeId=e115131383eee, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Antioxidants ：GLP1-RA、SGLT-2i及其联合治疗12个月对2型糖尿病患者氧化和抗氧化生物标志物的影响, objectType=article, longId=219643, objectId=0933219643a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0933219643a0, replyNumber=0, likeNumber=30, createdTime=2021-11-03, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0933219643a0, moduleTitle=Antioxidants ：GLP1-RA、SGLT-2i及其联合治疗12个月对2型糖尿病患者氧化和抗氧化生物标志物的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0933219643a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

联合治疗

2020-05-29

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Thorac Cancer：卡铂+白蛋白-紫杉醇联合治疗复发性小细胞肺癌（SCLC）的疗效

2022-03-25

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Oncologist：西妥昔单抗+伊立替康+贝伐单抗联合治疗未能改善伊立替康难治性转移性结直肠癌(mCRC)的患者PFS，但可改善OS

2022-03-15

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

硫胺素、维生素 C 和氢化可的松联合治疗脓毒症和感染性休克

2022-03-01

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Front Oncol：III期临床研究XELAVIRI评估一线贝伐珠单抗为基础的续观治疗对比联合治疗转移性结直肠癌（mCRC）患者的疗效

2022-02-23

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

LEUKEMIA：Erk1/2i 和 CDK4/6i 联合治疗复发难治性多发性骨髓瘤

2022-02-20

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

JAMA子刊：ICS/LABA联合治疗对早产儿相关肺部疾病有益

2022-02-17

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

BMC Cancer：韩国回顾性队列研究：非糖尿病血脂异常患者的降脂药物依从性和联合治疗对胃肠道肿瘤的影响

2022-02-15

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Transl Lung Cancer Res: 在EGFR突变晚期NSCLC患者使用EGFR-TKI治疗失败后，化疗-抗血管生成对比化疗-免疫治疗联合治疗的疗效

2022-02-10

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Transl Lung Cancer Res: Pembrolizumab（帕博利珠单抗）单药或联合治疗晚期非小细胞肺癌伴骨转移患者的疗效

2022-02-09

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

NEJM：纳武单抗联合治疗对晚期食管鳞状细胞癌的疗效分析

2022-02-06

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Front Immunol：联合治疗通过抑制Caspase-1/Gasdermin D诱导狼疮性肾炎细胞焦亡的新作用

2022-01-19

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

BMC Cancer：曲妥珠单抗和氟维司群联合治疗HR+/HER2+转移性乳腺癌患者的疗效和安全性

2022-01-12

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Chin J Cancer Res：阿帕替尼单药或联合治疗HER2阴性乳腺癌伴有胸壁转移患者的疗效：多中心II期临床研究

2021-12-22

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

辉瑞疫苗对奥密克戎的中和活性降低40多倍，我国新冠病毒中和抗体联合治疗药物获批丨新冠研究一周进展

2021-12-16

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

雷帕霉素和低剂量伊马替尼联合治疗肺动脉高压

2021-12-07

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

NEJM：绝经状态会影响腋窝淋巴结阳性乳腺癌患者化疗-内分泌联合治疗收益

2021-12-05

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

AJKD：利妥昔单抗+低剂量环磷酰胺+强的松联合治疗原发性膜性肾病的疗效

2021-12-03

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

ASCO2021:阿特珠单抗+贝伐珠单抗联合治疗对不可切除肝癌有益

2021-11-27

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Diabetes Obes Metab：每日2次艾塞那肽和达格列净单药或联合治疗对2型糖尿病肥胖患者肾功能标志物的影响

2021-11-05

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Antioxidants ：GLP1-RA、SGLT-2i及其联合治疗12个月对2型糖尿病患者氧化和抗氧化生物标志物的影响

2021-11-03

科室
- - 订阅+
  - 更多科室
工具
服务